S&P shifts Amneal view to negative

S&P said it revised the outlook for Amneal Pharmaceuticals LLC to negative.

“Our revised outlook reflects risk that Amneal will not meet our updated base case for 2020 of roughly $20 million in free cash flow and a mid-single-digit decline in revenue. After 2020, we expect Amneal’s business to stabilize and profitability to improve from cost-cutting efforts. We believe the company’s revenue trajectory is uncertain given its two recent guidance revisions and delays in the launches of new generic products,” said S&P in a press release.

S&P affirmed its B rating on the company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.